ライフサイエンスコーパス: raloxifene

1 t expressed N2BAsc (TAC/DOCAcRbm20(DeltaRRM)-raloxifene).

2 y to their target (biotin, desthiobiotin and raloxifene).

3 (cRbm20(DeltaRRM)-DMSO and cRbm20(DeltaRRM)-raloxifene).

4 phene (BT) scaffold common to arzoxifene and raloxifene.

5 diated oxygenation versus dehydrogenation of raloxifene.

6 per year and causes cataracts compared with raloxifene.

7 0.82; 95% CI, 0.68-0.99) in the women taking raloxifene.

8 ated by 17beta-estradiol (E2), tamoxifen, or raloxifene.

9 0002); no increase has been seen so far with raloxifene.

10 in the prevention trials; p<0.0001) and with raloxifene.

11 ffect on the potency or efficacy of the SERM raloxifene.

12 k of breast cancer who may benefit most from raloxifene.

13 at is not required for inhibition of PLD1 by raloxifene.

14 f raloxifene, and 94 (3.7%) with 120 mg/d of raloxifene.

15 n both cell lines after exposure to 10(-6) M raloxifene.

16 duction and is enhanced by acetazolamide and raloxifene.

17 ptor alpha and responded to retreatment with raloxifene.

18 relative benefits and harms of tamoxifen and raloxifene.

19 e estrogen receptor modulators tamoxifen and raloxifene.

20 k-reducing medications, such as tamoxifen or raloxifene.

21 ncer and cataracts compared with placebo and raloxifene.

22 d with the experimental structure of ERalpha-raloxifene.

23 efits from chemoprevention with tamoxifen or raloxifene.

24 of metabolism of the known CYP3A4 substrate raloxifene.

25 sence and absence of estradiol (1 nM) and/or raloxifene (100 nM).

26 Among controls, 6.6% had taken raloxifene; 2.4% had taken tamoxifen.

27 ge was significantly lower in those assigned raloxifene (50 events) compared with placebo (84 events;

28 Among cases, 3.3% had taken raloxifene; 6.2% had taken tamoxifen.

29 101; mean age, 67 years) were randomized to raloxifene 60 mg/d or placebo for a median of 5.6 years.

30 In postmenopausal women, raloxifene (60 mg per day for 5 years) and exemestane (2

31 In postmenopausal women, raloxifene (60 mg/d for 5 years) may also be considered.

32 Oral tamoxifen (20 mg/d) or raloxifene (60 mg/d) over 5 years.

33 Patients were randomly assigned to receive raloxifene, 60 mg/d (n = 2557), or 120 mg/d (n = 2572),

34 gen agonist (ethynyl estradiol) and the SERM raloxifene, 7-(R) was found to be a potent SERM that beh

35 After treatment with raloxifene, a dramatic increase in cell death occurred i

36 After the treatment with raloxifene, a dramatic increase in cell death was observ

37 Raloxifene, a drug known to undergo CYP3A-mediated react

38 Raloxifene, a mixed estrogen agonist/antagonist, was dev

39 ken together, these results demonstrate that raloxifene, a selective ER modulator, induces apoptosis

40 Raloxifene, a selective estrogen receptor (ER) modulator

41 e Use for The Heart (RUTH) trial showed that raloxifene, a selective estrogen receptor modulator, had

42 Raloxifene, a selective estrogen receptor modulator, imp

43 Raloxifene, a selective estrogen receptor modulator, is

44 Recently, our laboratory reported that raloxifene, a selective estrogen receptor modulator, pro

45 The effect of raloxifene, a selective estrogen-receptor modulator, on

46 Raloxifene, a synthetic steroid used in the prevention o

47 In endometrial cells, tamoxifen, but not raloxifene, acts like estrogen by stimulating the recrui

48 allows strong ERalpha AF-1 activity, whereas raloxifene allows less and ICI 182,780 (ICI) allows none

49 or (ER) modulators tamoxifen and LY117018 (a raloxifene analogue) partially reversed SPF45-mediated d

50 lness, 24 [11] years), 26 were randomized to raloxifene and 30 were randomized to placebo.

51 n of estradiol (E(2)) and two antiestrogens, raloxifene and 4-hydroxytamoxifen, in estrogen receptor

52 nces in fracture risk between risedronate or raloxifene and alendronate were small.

53 We report here the discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/

54 of virtual hits on drug databases identified raloxifene and bazedoxifene as potential inhibitors of I

55 Keoxifene was renamed raloxifene and became the first SERM for the treatment a

56 ind, randomized, placebo-controlled trial of raloxifene and CVD outcomes in 10 101 postmenopausal wom

57 ntly associated with serious adverse events; raloxifene and estrogen increase thromboembolic events;

58 e through wild-type (wt) ER, whereas others (raloxifene and GW7604) remain antiestrogenic.

59 important difference in the effects of TAM, raloxifene and ICI 182,780 on immunosurveillance in brea

60 ion, adverse events were similar between the raloxifene and placebo groups.

61 controlled, multiyear Study of Tamoxifen and Raloxifene and Raloxifene Use in the Heart clinical tria

62 ancer cells are not completely eradicated by raloxifene and rapidly expand if raloxifene treatment is

63 ses AF-1 activity in the presence of ICI and raloxifene and reverses the effect of the 537X mutation.

64 ollowing three NSABP protocols: the Study of Raloxifene and Tamoxifen (STAR), B-32, and B-35.

65 The benefits and risks of raloxifene and tamoxifen are described in tables that ca

66 Thus, raloxifene and tamoxifen impair E2-promoted DC different

67 Raloxifene and tamoxifen inhibited the differentiation o

68 In postmenopausal women, raloxifene and tamoxifen reduce the risk of ER-positive

69 Raloxifene and tamoxifen regulated only 27% of the same

70 Effects of raloxifene and tamoxifen were estimated from STAR and th

71 lective estrogen receptor modulators (SERM), raloxifene and tamoxifen, can perturb DC development and

72 Newer agents such as raloxifene and the aromatase inhibitors need to be evalu

73 .7%) with placebo, 82 (3.2%) with 60 mg/d of raloxifene, and 94 (3.7%) with 120 mg/d of raloxifene.

74 medications (bisphosphonates, teriparatide, raloxifene, and denosumab) compared with placebo, usual

75 d by antiestrogen ligands such as tamoxifen, raloxifene, and droloxifen, which was confirmed in chrom

76 women, bisphosphonates, parathyroid hormone, raloxifene, and estrogen reduce primary vertebral fractu

77 nclude agents such as tamoxifen, toremifene, raloxifene, and fulvestrant.

78 ability of the ER ligands 17beta-estradiol, raloxifene, and ICI 182,780 to effectively block the cel

79 /p160 interactions, whereas 4(OH)-tamoxifen, raloxifene, and ICI-182,780 inhibit these interactions.

80 OHT and by 10-20 microm 17beta-estradiol and raloxifene, and occurs in ER-negative cells.

81 fine the complex tissue responses to 4HT and raloxifene, and suggests that these ligands can have a b

82 e treated either with 17beta-estradiol (E2), raloxifene, and tamoxifen for 18 h.

83 in bone-related activities regulated by E2, raloxifene, and tamoxifen were also distinct.

84 egulated in ERalpha cells in response to E2, raloxifene, and tamoxifen were distinct from those regul

85 in U2OS-ERalpha and U2OS-ERbeta cells by E2, raloxifene, and tamoxifen, respectively.

86 Raloxifene, another of these drugs, is being used to pre

87 ulators (SERMs) 4-hydroxytamoxifen (4HT) and raloxifene are able to elevate SRC-1 and SRC-3 protein l

88 Tamoxifen and raloxifene are associated with similar patterns of cogni

89 n studies such as the Study of Tamoxifen and Raloxifene are available to women at increased risk of d

90 Moreover, ICI and raloxifene are more efficient than tamoxifen in promotin

91 Consistent with this, ICI and raloxifene are more potent than tamoxifen in promoting E

92 Tamoxifen and raloxifene are selective estrogen receptor modulators th

93 oestrogen-receptor modulators--tamoxifen and raloxifene--are so far the only medical options approved

94 Tamoxifen, raloxifene, aromatase inhibition, and fenretinide.

95 rogen receptor modulators (SERMs; tamoxifen, raloxifene, arzoxifene, and lasofoxifene) with placebo,

96 revention agents were identified: tamoxifen, raloxifene, arzoxifene, lasofoxifene, exemestane, and an

97 itor exemestane in addition to tamoxifen and raloxifene as a breast cancer prevention medication, alt

98 by Spurgeon et al which evaluates oral SERM raloxifene as a potential therapeutic agent for HPV-asso

99 week; they could have received tamoxifen or raloxifene as long as they were on a stable dose.

100 Early findings on the use of tamoxifen or raloxifene as prophylaxis against breast cancer have bee

101 as efficacious as tamoxifen and superior to raloxifene at the corresponding doses.

102 ed estrogens with the antagonists tamoxifen, raloxifene, bazedoxifene, or fulvestrant.

103 ery P450 tested except CYP2E1 was capable of raloxifene bioactivation, based on glutathione adduct fo

104 as seen in the STAR (Study of Tamoxifen and Raloxifene) breast cancer prevention trial and in other

105 d threshold of 1.66% for use of tamoxifen or raloxifene but >or= 1.66% when using the updated model.

106 Tamoxifen was more effective than raloxifene but also increased the incidence of endometri

107 nding antisynergy (21-fold) between PAPS and raloxifene, but not DHEA.

108 incidence of thromboembolic events more than raloxifene by 4 cases in 1000 women.

109 en reduced breast cancer incidence more than raloxifene by 5 cases in 1000 women.

110 There was no evidence that raloxifene caused an early increase in risk of cardiovas

111 ic events by 4 to 7 per 1000 women per year; raloxifene causes fewer events than tamoxifen.

112 the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) trial, beginning 18 months after ST

113 h outcomes to calculate the net benefit from raloxifene compared with placebo and tamoxifen compared

114 in the PANSS general symptom scores for the raloxifene compared with the placebo (beta = -3.72; 95%

115 r risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown.

116 Raloxifene competes with endogenous estrogen for binding

117 ion in adult mice was triggered by injecting raloxifene (cRbm20(DeltaRRM)-raloxifene), with dimethyl

118 or multiple risk factors for CHD to 60 mg of raloxifene daily or placebo and followed them for a medi

119 trial, low strength of evidence); high-dose raloxifene decreased risk for MCI but not for dementia (

120 Raloxifene did not antagonize the action of estradiol on

121 Raloxifene did not significantly affect the risk of CHD.

122 is model using various ER ligands, including Raloxifene, Diethylstilbestrol, E2, and 4-hydroxytamoxif

123 putative ester, formed by the conjugation of raloxifene diquinone methide with a carboxylic acid moie

124 Unlike tamoxifen, raloxifene does not increase the incidence of endometria

125 However, in vitro, raloxifene does not share the pro-estrogenic effects of

126 The results demonstrated that raloxifene does not significantly alter androgen recepto

127 (ICI), as well as a selective ER modulator, raloxifene, efficiently clear cancer and its precursor l

128 to sham control rats (p < 0.05), whereas E2, raloxifene, EM652, and alendronate regulated 613, 765, 6

129 e risk for thromboembolic events (tamoxifen, raloxifene), endometrial cancer (tamoxifen), or stroke (

130 or dihydrotestosterone, but differently from raloxifene, estren alters the activity of Elk-1, CCAAT e

131 Raloxifene, estrogen, and estrogen-progestin increased t

132 ent data from the MORE (Multiple Outcomes of Raloxifene Evaluation) trial have evaluated health-relat

133 Following treatment with raloxifene, evidence of apoptosis, including change in n

134 estradiol levels greater than 10 pmol/L with raloxifene for 4 years would have avoided 47% of breast

135 lex decision of whether to take tamoxifen or raloxifene for breast cancer chemoprevention.

136 sized to play an important role in orienting raloxifene for dehydrogenation through a combination of

137 opausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women.

138 enistein), but not antagonists (tamoxifen or raloxifene), for 48 h inhibits GR-mediated MMTV-LUC tran

139 tine use of medications,such as tamoxifen or raloxifene, for risk reduction of primary breast cancer

140 gs diclofenac (DCF), troglitazone (TGZ), and raloxifene, for which we observed known metabolic oxidat

141 f 17 beta-estradiol, ICI 182,780, tamoxifen, raloxifene, genistein, or daidzein.

142 n the tamoxifen group (57 cases) than in the raloxifene group (80 cases) (incidence, 1.51 vs 2.11 per

143 mboembolic events occurred less often in the raloxifene group (RR, 0.70; 95% CI, 0.54-0.91).

144 tradiol levels greater than 10 pmol/L in the raloxifene group had a rate of breast cancer that was 76

145 symptom assessment analyses, the 9769 in the raloxifene group reported greater mean symptom severity

146 adder control problems, whereas women in the raloxifene group reported more musculoskeletal problems,

147 BMD at the femoral neck; however, within the raloxifene group, lower baseline CrCl was associated wit

148 ifferences existed between the tamoxifen and raloxifene groups in patient-reported outcomes for physi

149 lacebo (RR, 0.60; 95% CI, 0.38-0.95 for both raloxifene groups).

150 vascular risk at baseline, those assigned to raloxifene had a significantly lower risk of cardiovascu

151 rmation activity below that of sham, whereas raloxifene had little effect on these genes.

152 Raloxifene had no effect on the incidence of coronary ev

153 As compared with placebo, raloxifene had no significant effect on the risk of prim

154 Raloxifene has been shown in placebo-controlled trials t

155 for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast can

156 and can be used in premenopausal women, but raloxifene has fewer side-effects.

157 Our data demonstrate that tamoxifen and raloxifene have differential effects on PLD catalytic ac

158 Tamoxifen and raloxifene have limited patient acceptance for primary p

159 eatment strategies, such as the antiestrogen raloxifene, have shown promising results; however, furth

160 modified estrogen receptor plus tamoxifen or Raloxifene) hearts.

161 Raloxifene-hERalpha and MOX-hERalpha exhibited similar b

162 ound to ERalpha in an orientation similar to raloxifene; however, a number of residues adopted differ

163 ratio [HR], 1.01 [95% CI, 0.85 to 1.21]) or raloxifene (HR, 1.18 [CI, 0.96 to 1.46]) and alendronate

164 Raloxifene hydrochloride is a selective estrogen recepto

165 Adjunctive raloxifene hydrochloride, 120 mg/d, or placebo for 12 we

166 Raloxifene hydrochloride, 120 mg/d, reduces illness seve

167 effectiveness of SERMs such as tamoxifen and raloxifene in breast cancer depends on their antiestroge

168 he comparative abilities of tamoxifen versus raloxifene in breast cancer prevention are currently bei

169 addition, new information on the effects of raloxifene in breast cancer prevention, cardiovascular d

170 ers and SERM nonusers, suggesting a role for raloxifene in endometrial cancer prevention and individu

171 are minimally regulated by estradiol (E2) or raloxifene in ERalpha-positive MCF-7 human breast cancer

172 rities and differences between tamoxifen and raloxifene in estrogen-responsive tissues.

173 The benefits of raloxifene in reducing the risks of invasive breast canc

174 the present study investigated the effect of raloxifene in the androgen-sensitive human prostate canc

175 patient, 5-year comparison of tamoxifen and raloxifene in the prevention of breast cancer.

176 This large trial of raloxifene in this patient population offers a promising

177 the present study investigated the effect of raloxifene in three well-characterized, androgen-indepen

178 ed to tamoxifen and 168 in those assigned to raloxifene (incidence, 4.30 per 1000 vs 4.41 per 1000; r

179 In conclusion, raloxifene increases BMD at both the hip and the spine a

180 Here, we show that both tamoxifen and raloxifene induce the recruitment of corepressors to tar

181 However, raloxifene induced caspase-dependent cleavage of BAD to

182 ility that caspase activation is involved in raloxifene-induced apoptosis, cells were treated with th

183 BAD resistant to caspase 3 cleavage blocked raloxifene-induced apoptosis.

184 These results demonstrate that raloxifene induces apoptosis through the cleavage of BAD

185 that the mixed estrogen agonist/antagonist, raloxifene, induces apoptosis in androgen-independent hu

186 Furthermore, tamoxifen stimulation and raloxifene inhibition of PLD activities are independent

187 ositive and -negative cells in vivo, whereas raloxifene inhibits PLD activity in these same cell type

188 titin (N2BAsc), which, within 3 weeks after raloxifene injection, made up approximately 45% of total

189 rols, reduced tamoxifen dosing and/or use of raloxifene is advised with this model.

190 Raloxifene is as effective as tamoxifen in reducing the

191 Raloxifene is associated with a lower risk of thromboemb

192 iently by SULT2A1 in vitro, yet unlike DHEA, raloxifene is not sulfated in vivo.

193 nown whether treatment for osteoporosis with raloxifene is safe or effective in those with chronic ki

194 Before raloxifene is used for prevention of cardiovascular even

195 One of these compounds, raloxifene, is used for the prevention of osteoporosis,

196 erent for each pharmaceutical agent and that raloxifene maintained more genes at sham levels than any

197 Raloxifene maintains bone density (estrogen-like effect)

198 lecular mechanism of apoptosis suggests that raloxifene may be a therapeutic agent for human bladder

199 Raloxifene may prevent vertebral fractures but may not i

200 However, raloxifene-mediated time-dependent inhibition only occur

201 cRbm20(DeltaRRM)-raloxifene mice expressed large titins in the hearts, ca

202 was normalized in TAC/DOCA cRbm20(DeltaRRM)-raloxifene mice that expressed N2BAsc.

203 icate that a prolonged treatment period with raloxifene might be required to prevent recurrence of ne

204 fference between the tamoxifen (n = 973) and raloxifene (n = 1010) groups (P>.2).

205 y assigned to receive 60 mg/d or 120 mg/d of raloxifene (n = 4843) or matching placebo (n = 2447) for

206 n's estradiol level may alter the effects of raloxifene on breast cancer and other outcomes.

207 l insights into the effects of tamoxifen and raloxifene on cognitive function in older women.

208 We provide detailed results of the effect of raloxifene on coronary outcomes over time and for 24 sub

209 udy, we compare the effects of tamoxifen and raloxifene on PLD in the ER-positive mammary epithelial

210 ausal women with osteoporosis, the effect of raloxifene on rate of change of bone mineral density (BM

211 The effect of raloxifene on the incidence of coronary events differed

212 In this study, we examined the effect of raloxifene on the TSU-PR1 cell line.

213 cells was completely inhibited by 500 nmol/L raloxifene or 500 nmol/L 4-hydroxytamoxifen, these conce

214 of PI-9, and makes tamoxifen (TAM), but not raloxifene or ICI 182,780, a potent inducer of PI-9.

215 PI-9 was not induced by raloxifene or ICI 182,780.

216 by tamoxifen but not by other SERMs, such as raloxifene or ICI182,780 (Fulvestrant).

217 Risks and benefits of treatment with raloxifene or tamoxifen depend on age, race, breast canc

218 number of deaths (101 vs 96 for tamoxifen vs raloxifene) or in causes of death.

219 dent and was nearly absent when ICI 182,780, raloxifene, or 4-hydroxytamoxifen were bound to the ERs.

220 ERalpha and increased the reactivity of the raloxifene- or ICI 182,780-bound ERalpha, with probes th

221 s without concurrent changes in the rates of raloxifene oxygenation.

222 tazolamide (oral or intra-arterial) and oral raloxifene (P=0.0248, P<0.0001, and P=0.0006, respective

223 dence suggesting the antagonistic effects of raloxifene persisted in the reproductive tract after tre

224 en with osteoporosis, and both tamoxifen and raloxifene prevent breast cancer in high-risk women.

225 d, estrogen, parathyroid hormone (1-34), and raloxifene prevent vertebral fractures more than placebo

226 Moreover, continuous treatment of mice with raloxifene prevented the emergence of recurrent disease

227 Raloxifene produced a greater reduction in the PANSS tot

228 y the SERMs trans-hydroxytamoxifen (TOT) and raloxifene (Ral) or ICI 182,780 (ICI) and by estradiol (

229 owever, among those with a fracture history, raloxifene recipients experienced more nonvertebral frac

230 Tamoxifen and raloxifene reduce estrogen receptor-positive breast canc

231 Tamoxifen and raloxifene reduce the incidence of estrogen receptor-pos

232 Tamoxifen and raloxifene reduce the risk of breast cancer in women at

233 Raloxifene reduced the risk of clinical vertebral fractu

234 Raloxifene reduces breast cancer risk in women with oste

235 d in part on the improved safety profile for raloxifene relative to the standard treatment of tamoxif

236 use for breast cancer risk reduction whereas raloxifene requires further study.

237 formation activity and that ovariectomy plus raloxifene resembles sham more closely than ovariectomiz

238 d to formation of estrogen receptor-positive raloxifene-responsive mammary carcinomas with features o

239 r risk whether or not they were treated with raloxifene (risk difference, -0.1%; 95% CI, -0.8% to 0.6

240 tio, 0.70 [95% CI, 0.59 to 0.82]; 4 trials), raloxifene (risk ratio, 0.44 [CI, 0.27 to 0.71]; 2 trial

241 atio, 1.93 [CI, 1.41 to 2.64]; 4 trials) and raloxifene (risk ratio, 1.60 [CI, 1.15 to 2.23]; 2 trial

242 of uterine cancer with tamoxifen and 23 with raloxifene (RR, 0.62; 95% CI, 0.35-1.08).

243 ew results from STAR (Study of Tamoxifen and Raloxifene) showed that tamoxifen reduced breast cancer

244 en receptor modulator (SERM), tamoxifen, and raloxifene side-by-side in in vitro and in vivo MCF-7 br

245 xypurinol or aldehyde oxidase (AO) inhibitor raloxifene significantly decreased NO generation from ni

246 en Receptor Modulators (SERMs) tamoxifen and raloxifene, so called for their ability to function as E

247 The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as ef

248 t provided data on the harms of tamoxifen or raloxifene, studies of the costs of chemoprevention, and

249 The raloxifene study of postmenopausal women with osteoporos

250 wn without cardiomyopathy is achievable with raloxifene, suggesting toxicity is not simply from Cre.

251 olved in the positioning and/or catalysis of raloxifene supporting dehydrogenation were identified wi

252 are endometrial cancer risks associated with raloxifene, tamoxifen, and nonusers of a selective estro

253 The SERMs investigated in this study include raloxifene, tamoxifen, and the tamoxifen metabolites 4-h

254 t uterus had a better benefit/risk index for raloxifene than for tamoxifen.

255 ethinyl estradiol, the benzothiophene SERM, raloxifene, the benzopyran SERM, (S)-3-(4-hydroxyphenyl)

256 Raloxifene therapy for 4 years did not significantly aff

257 ated the recurrence of cervical cancer after raloxifene therapy in our preclinical model of human pap

258 y confirm CYP3A4-mediated dehydrogenation of raloxifene to a reactive diquinone methide but also sugg

259 hanism of CYP3A4-mediated dehydrogenation of raloxifene to a reactive diquinone methide, while exclud

260 Dehydrogenation of raloxifene to an electrophilic diquinone methide interme

261 ent studies have demonstrated the ability of raloxifene to form reactive intermediates and act as a m

262 hat control the selective dehydrogenation of raloxifene to its protein-binding intermediate.

263 ective ability of the SERM tamoxifen but not raloxifene to regulate miR-451 and 14-3-3zeta may assist

264 ne methide but also suggest a novel route of raloxifene toxicity.

265 adicated by raloxifene and rapidly expand if raloxifene treatment is ceased.

266 Irrespective of kidney function, raloxifene treatment was associated with a greater incre

267 cancer in mice re-exposed to estrogen after raloxifene treatment, despite evidence suggesting the an

268 levels of Bax, Bcl-2, and Bcl-X(L) following raloxifene treatment.

269 ast and Bowel Project Study of Tamoxifen and Raloxifene trial, a prospective, double-blind, randomize

270 being compared in the Study of Tamoxifen and Raloxifene trial.

271 In addition, tamoxifen and raloxifene, two selective estrogen receptor modulators t

272 The Raloxifene Use for The Heart (RUTH) trial showed that ra

273 The Raloxifene Use for the Heart (RUTH) trial was an interna

274 tiyear Study of Tamoxifen and Raloxifene and Raloxifene Use in the Heart clinical trials have recentl

275 developing endometrial cancer compared with raloxifene users (OR = 3.0; 95% CI, 1.3 to 6.9).

276 Endometrial tumors in raloxifene users had a more favorable histologic profile

277 Raloxifene users had significantly lower odds of endomet

278 actors, the odds of endometrial cancer among raloxifene users was 50% that of nonusers (odds ratio [O

279 breast cancer, and pulmonary embolism), and raloxifene (venous thromboembolism).

280 studies of medication initiators: a study of raloxifene versus alendronate in 1-year nonvertebral fra

281 n and in comparing the benefits and risks of raloxifene versus tamoxifen.

282 positive symptom scores (beta for change in raloxifene vs placebo, -1.92; 95% CI, -3.83 to 0.00; P =

283 esigned to evaluate the relative efficacy of raloxifene vs tamoxifen in reducing the incidence of inv

284 Raloxifene was approved in 2007 by the FDA for the chemo

285 ifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the

286 al stroke according to group assignment, but raloxifene was associated with an increased risk of fata

287 e of recurrent disease seen in mice in which raloxifene was discontinued.

288 in cellular morphology after treatment with raloxifene was no longer observed when cells were pretre

289 in cellular morphology after treatment with raloxifene was no longer observed when cells were pretre

290 onary events, the overall lack of benefit of raloxifene was similar across the prespecified subgroups

291 Tamoxifen and raloxifene were effective only against estrogen receptor

292 ties of tazarotene, adapalene, acitretin and raloxifene were identified.

293 AF2ER activation levels with ICI, OHT, and raloxifene were parallel with the degree of AF2ER-LBD ho

294 eatment with bisphosphonates, calcitonin, or raloxifene were treated as competing risks.

295 rials, 3 involving tamoxifen and 1 involving raloxifene, were selected.

296 esults from the NSABP Study of Tamoxifen and Raloxifene, which compares the risk-reducing efficacy as

297 In silico docking predicts that raloxifene, which is considerably larger than DHEA, can

298 sed prevention trials comparing tamoxifen or raloxifene with placebo were included.

299 tion, pairing the estrogen response modifier raloxifene with the c-Met/VEGFR2 kinase inhibitor caboza

300 ed by injecting raloxifene (cRbm20(DeltaRRM)-raloxifene), with dimethyl sulfoxide (DMSO)-injected mic